mouse panc02  (ATCC)

Journal: Cell Reports Medicine

Article Title: ENPP1 inhibitor with ultralong drug-target residence time as an innate immune checkpoint blockade cancer therapy

doi: 10.1016/j.xcrm.2025.102336

Figure Lengend Snippet: STF-1623 controls Panc02 pancreatic tumor growth by activating anti-cancer immunity (A and B) BALB/c female mice with established subcutaneous Panc02 tumors received treatment indicated. On day 12 of the study, tumors were processed for flow cytometry: the percentage of IA-IE + CD206 low M1 macrophage (F4/80 + GR-1 − ) over IA-IE − CD206 high M2 macrophage, the number of CD335 + CD3 − NK cells, CD335 + CD3 + NKT cells, CD4 + CD3 + T cells, and CD8 + CD3 + T cells per gram of tumors, and the ratio of CD8 + T cells over Foxp3 + CD4 + Treg cells (A), CD69 + CD4 + T cells, PD-1 + CD4 + T cells, Ki67 + CD4 + T cells, CD69 + CD8 + T cells, PD-1 + CD8 + T cells, and Ki67 + CD8 + T cells (B). Mean ± SD is plotted, n = 6 mice for vehicle and STF-1623 groups, and n = 3 for all other combination therapy groups. (C) BALB/c female mice with established Panc02 tumors received the treatment as indicated. Mean ± SEM of tumor volume is plotted, n = 9–12 mice. Spider plots of individual tumor growth are shown. (D) Percent weight change of mice in (C) on day 45 compared to day 1 of the study. Mean ± SD is plotted, n = 9–12 mice. NK, natural killer; NKT, natural killer T; Treg, regulatory T cells; IR. ionizing radiation. p values were calculated by two-sided unpaired t test unless otherwise noted. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001; p value is shown if between 0.05 and 0.1.

Article Snippet: Mouse: Panc02 , ATCC , Cat# CRL-2553.

Techniques: Flow Cytometry

Journal: Research

Article Title: Novel Combination of Irreversible Electroporation and Allogenic Chimeric Antigen Receptor T-Cell Therapy Synergizes Therapeutic Outcomes in a Preclinical Human Pancreatic Cancer Mouse Model

doi: 10.34133/research.1105

Figure Lengend Snippet: (A) Calculated irreversible electroporation (IRE) lethal electric field thresholds for Pan02 mouse pancreatic cancer using a 3-dimensional (3D) collagen hydrogel; mean ± SD; n = 5. (B) COMSOL Multiphysics finite element model (FEM) representing subcutaneous mouse tumors with a 5-mm spacing shown. (C) Simulated percent tumor coverage by the lethal electric field using the subcutaneous FEM with randomized tissue conductivities and tumor sizes (4 to 8 mm); mean ± SD; n = 30. (D) In Vivo Imaging System (IVIS) imaging of FLuc-eGFP + Pan02 cells in immunodeficient NOD/SCID/IL2gc-KO (NSG) mice (m) follows complete ablation and subsequent microtumor recurrence after IRE treatment at 2,500 V/cm; n = 6. (E) Tumor scabbing and flattening at day 3 post-treatment. (F) Total photon flux within the tumor region of interest from the IVIS images; mean and range presented; multiple 2-tailed t tests between the data compared to the initial day 0 total photon flux; n = 6. (G) Measured tumor size over time from tumor inoculation; mean and range presented; multiple 2-tailed t tests between the data compared to pre-treatment tumor size on day 30; n = 6. ** P < 0.01; **** P < 0.0001. FLuc-eGFP, firefly-luciferase-enhanced green fluorescent protein. SAT, subcutaneous fat.

Article Snippet: Pan02 mouse pancreatic cancer cells (Cytion, 300501), AsPC-1 human pancreatic cancer cells (American Type Culture Collection [ATCC], CRL-1682), and Jurkat immortalized human T lymphocytes (ATCC, TIB-152) were cultured in RPMI 1640 medium (Thermo Fisher, 11875093) supplemented with 10% (v/v) fetal bovine serum (Fisher Scientific, FB12999102) and 1% (v/v) 10,000 U/ml penicillin–streptomycin (Gibco, 16140122).

Techniques: Electroporation, In Vivo Imaging, Imaging, Luciferase